Unknown

Dataset Information

0

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.


ABSTRACT: AIM:To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin. METHODS:In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ?7.5% and ?11.0% (?58 and ?97 mmol/mol) with metformin ?1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of E5/S100 or E15/S100. The primary endpoint was change from baseline in HbA1c at Week 26. RESULTS:At Week 26, least squares mean HbA1c reductions from baseline were greater with E5/S100 (-1.5%) and E15/S100 (-1.5%) than with individual agents (-1.0%, -1.1% and -1.1% for E5, E15 and S100, respectively; P < .001 for all comparisons). HbA1c <7.0% (<53 mmol/mol) was achieved by 26.4%, 31.9%, 32.8%, 52.3% and 49.2% of patients in the E5, E15, S100, E5/S100 and E15/S100 groups, respectively. Fasting plasma glucose reductions were significantly greater with E5/S100 and E15/S100 compared with individual agents. Body weight and systolic blood pressure (SBP) significantly decreased with E5/S100 and E15/S100 vs S100 alone. Glycaemic control, body weight and SBP effects of ertugliflozin were maintained to Week 52. Genital mycotic infections were more common among ertugliflozin-treated patients compared with those treated with S100. Incidences of symptomatic hypoglycaemia and adverse events related to hypovolaemia or urinary tract infection were similar among groups. CONCLUSIONS:In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents.

SUBMITTER: Pratley RE 

PROVIDER: S-EPMC5947297 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

Pratley Richard E RE   Eldor Roy R   Raji Annaswamy A   Golm Gregory G   Huyck Susan B SB   Qiu Yanping Y   Sunga Sheila S   Johnson Jeremy J   Terra Steven G SG   Mancuso James P JP   Engel Samuel S SS   Lauring Brett B  

Diabetes, obesity & metabolism 20180125 5


<h4>Aim</h4>To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin.<h4>Methods</h4>In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ≥7.5% and ≤11.0% (≥58 and ≤97 mmol/mol) with metformin ≥1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of  ...[more]

Similar Datasets

| S-EPMC5836931 | biostudies-literature
| S-EPMC5801240 | biostudies-literature
| S-EPMC8099972 | biostudies-literature
| S-EPMC6593724 | biostudies-literature
| S-EPMC6618047 | biostudies-literature
| S-EPMC5801244 | biostudies-literature
| S-EPMC4019272 | biostudies-literature
| S-EPMC7994479 | biostudies-literature
| S-EPMC9314942 | biostudies-literature
| S-EPMC5969239 | biostudies-literature